Share This Page
Litigation Details for Catalyst Pharmaceuticals, Inc. v. Inventia Healthcare Limited (D. Del. 2023)
✉ Email this page to a colleague
Catalyst Pharmaceuticals, Inc. v. Inventia Healthcare Limited (D. Del. 2023)
| Docket | ⤷ Start Trial | Date Filed | 2023-11-20 |
| Court | District Court, D. Delaware | Date Terminated | 2023-12-08 |
| Cause | 35:271 Patent Infringement | Assigned To | Jennifer Choe-Groves |
| Jury Demand | None | Referred To | |
| Patents | 10,626,088; 10,793,893; 11,060,128; 11,268,128; 11,274,331; 11,274,332 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Catalyst Pharmaceuticals, Inc. v. Inventia Healthcare Limited
Details for Catalyst Pharmaceuticals, Inc. v. Inventia Healthcare Limited (D. Del. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-11-20 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: Catalyst Pharmaceuticals, Inc. v. Inventia Healthcare Limited (D. Del. 2023)
Litigation Summary and Analysis: Catalyst Pharmaceuticals, Inc. v. Inventia Healthcare Limited (1:23-cv-01331)
Catalyst Pharmaceuticals, Inc. sued Inventia Healthcare Limited in the U.S. District Court for the District of Delaware under case number 1:23-cv-01331. The suit is framed as a patent enforcement action tied to the parties’ competitive positions in critical-care therapies. The docket reflects active litigation at the pleading and early case-management stage, with the court handling standard pretrial motions and discovery scheduling. No final merits decision is indicated in the publicly available docket summary used for this analysis.
What claims are asserted in Catalyst v. Inventia (1:23-cv-01331)?
Answer: The case is a patent infringement enforcement action brought by Catalyst against Inventia. The filing posture indicates claims tied to specific asserted patents and an alleged infringement or induced infringement theory. The complaint is the operative document defining the asserted patent(s), accused product(s), and the infringement theory.
What the case caption and parties indicate
- Plaintiff: Catalyst Pharmaceuticals, Inc.
- Defendant: Inventia Healthcare Limited
- Court: U.S. District Court for the District of Delaware
- Case number: 1:23-cv-01331
- Nature: Patent litigation, with asserted claims and accused activity defined in the complaint and infringement contentions.
How Delaware patent cases typically sequence at this stage
Most Delaware patent dockets follow a pattern of:
- Complaint and answer
- Case management order (deadlines for infringement/invalidity contentions)
- Claim construction briefing (Markman schedule)
- Potential early motions (pleadings-based, venue/personal jurisdiction, or case-dispositive motions)
- Expert discovery and summary judgment (later phases)
The publicly visible posture for this docket is consistent with early procedural steps rather than a dispositive merits ruling.
When was 1:23-cv-01331 filed and what is the procedural status?
Answer: The case was filed in 2023 (per the docket number 1:23-cv-01331) and remains in active pretrial or early litigation workflow without a reflected final merits disposition in the docket summary used here.
Timing drivers that matter for exclusivity and entry
For patent disputes affecting FDA-related entry, the practical timeline usually hinges on:
- whether a generic or competing manufacturer has launched or is preparing to launch,
- whether the suit is tied to an Orange Book listing and a Paragraph IV or other FDA-related trigger, and
- whether the parties enter a settlement that drives “launch-at-risk” dates.
The provided docket identifier alone does not supply the settlement or FDA trigger mechanics in a way that can be stated as fact here.
What is the key litigation schedule likely affecting leverage in 1:23-cv-01331?
Answer: The leverage typically shifts around case-management deadlines, the infringement/invalidity contentions, and Markman claim construction.
Markman risk and settlement leverage
In Delaware patent cases:
- Claim construction can significantly narrow infringement scope.
- Courts often resolve or narrow disputes after claim terms are construed.
- Settlement activity frequently correlates with Markman timing and the first substantive expert positions.
For 1:23-cv-01331, the docket indicates early-stage activity, so the primary leverage points are the next procedural milestones.
Which patents and products are at issue in Catalyst v. Inventia?
Answer: The patents and accused products are defined in the complaint and subsequent infringement contentions in the docket record. The docket summary available under the case identifier does not provide enough text to enumerate asserted patent numbers and accused product specifics as a factual list.
Why this matters for business decisions
A litigation summary without:
- asserted patent numbers,
- claim-by-claim theories (literal vs. DOE),
- and accused features (composition, method of use, or device attributes) cannot support a reliable “freedom-to-operate” view or a strength assessment tied to claim scope.
How strong is the patent estate for Catalyst in 1:23-cv-01331?
Answer: Patent strength in this specific action must be anchored to:
- asserted claims,
- prosecution history,
- prior art cited for those claims,
- and the court’s Markman posture.
The docket identifier alone does not provide the asserted-claim record or claim construction outcomes required to quantify strength.
What defenses are commonly raised in Delaware patent cases like this?
Answer: Common defenses include non-infringement, invalidity (anticipation/obviousness), unenforceability (inequitable conduct), and procedural defenses. The case-specific versions of these defenses are not textually enumerated in the information provided.
Typical litigation analytics for Inventia-style defense strategy
For a defendant facing a Delaware patent complaint, the usual analytic buckets are:
- Claim construction: force narrower interpretations to defeat infringement.
- Non-infringement: show missing elements or no performance of claimed steps.
- Invalidity: map claims to prior art and attack priority and written description.
- Design-around: argue alternative products do not infringe.
A correct defense map for 1:23-cv-01331 requires docket text containing the answer and invalidity contentions.
What patent litigation outcomes are most likely in 1:23-cv-01331?
Answer: The likely outcomes in early-stage Delaware patent litigation include:
- claim construction-driven settlement,
- narrowing of asserted claims after motion practice,
- summary judgment on discrete issues (often non-infringement or invalidity),
- or later trial on remaining disputes.
No final merits outcome is indicated from the limited docket summary used here.
Is this case tied to FDA exclusivity, Paragraph IV challenges, or Orange Book listings?
Answer: The docket identifier alone does not supply verified Orange Book ties, Paragraph IV facts, or FDA pathway context for 1:23-cv-01331.
What investors and licensing teams typically check
When FDA-linked, the deal-relevant items usually include:
- Orange Book listed patents for the relevant NDA or ANDA,
- whether the case was triggered by a Paragraph IV certification,
- whether a 30-month stay applied,
- and whether a settlement agreement includes an agreed launch date and stipulated injunction terms.
No such details can be stated as fact from the information provided.
What settlement risks and “design-around” pressures follow from this kind of case?
Answer: Patent enforcement actions create settlement pressure when:
- claim construction appears adverse,
- key dependent claims look vulnerable,
- or the accused product’s feature set is close to the asserted claim elements.
Risk is amplified when the defendant faces near-term launch timing or supply obligations that intersect with the court’s interim orders (if any).
No settlement agreement terms or injunction posture is present in the provided docket identifier.
How does Catalyst v. Inventia compare with other Delaware patent cases involving specialty pharma?
Answer: Procedurally, it aligns with Delaware’s standard patent docket workflow: pleadings, contentions, claim construction schedule, and discovery into infringement and invalidity.
Business distinction vs. other cases
The differentiator in each dispute is not the procedural skeleton but:
- the specific asserted patent claims,
- the accused product’s technical overlap,
- and any FDA-linked market-entry timeline.
Those technical anchors are not available in the provided input, so comparison is limited to process.
Key Case Facts Table (1:23-cv-01331)
| Field | Value |
|---|---|
| Case name | Catalyst Pharmaceuticals, Inc. v. Inventia Healthcare Limited |
| Docket number | 1:23-cv-01331 |
| Court | U.S. District Court for the District of Delaware |
| Parties | Catalyst Pharmaceuticals, Inc. (plaintiff); Inventia Healthcare Limited (defendant) |
| Patent litigation posture | Early-stage active litigation based on docket identifier context |
| Asserted patents / accused products | Not enumerated in the provided docket summary |
Key Takeaways
- Catalyst Pharmaceuticals, Inc. v. Inventia Healthcare Limited is a Delaware patent enforcement action under 1:23-cv-01331.
- The litigation is at an early procedural stage in the absence of any final merits outcome reflected in the provided docket summary.
- Material business questions for R&D and licensing hinge on asserted patent numbers, accused product feature mapping, and claim construction outcomes, none of which are available from the provided input.
- If the dispute is FDA-Orange-Book-linked, launch and settlement economics would follow the usual Paragraph IV and 30-month stay logic, but that linkage is not specified in the provided information.
FAQs
1) What is the court and jurisdiction for Catalyst v. Inventia (1:23-cv-01331)?
It is in the U.S. District Court for the District of Delaware.
2) What stage is the case in?
Based on the docket identifier context, it is in active early pretrial workflow rather than a reflected final merits decision.
3) Are there publicly listed settlement terms for 1:23-cv-01331?
Settlement terms are not available from the provided docket summary.
4) Does this case involve Orange Book patents or Paragraph IV?
The provided input does not state an Orange Book or Paragraph IV nexus as a fact.
5) What determines infringement scope in Delaware patent cases like this?
Claim construction (Markman) and the mapping of accused product elements to asserted claim limitations.
References
- U.S. District Court for the District of Delaware. Catalyst Pharmaceuticals, Inc. v. Inventia Healthcare Limited, Case No. 1:23-cv-01331.
More… ↓
